Home Stock

Stock Research: Eli Lilly

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Eli Lilly

NYQ:LLY US5324571083
73
  • Value
    57
  • Growth
    64
  • Safety
    Safety
    72
  • Combined
    83
  • Sentiment
    51
  • 360° View
    360° View
    73
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Eli Lilly and Company is a medicine company that discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. It operates in the pharmaceutical industry, with products including Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity, and Zepbound, among others. The company operates globally. In the last fiscal year, the company had a market cap of $731,415 million, profits of $36,624 million, and revenue of $45,043 million with 47,000 employees.

more

ANALYSIS: With an Obermatt 360° View of 73 (better than 73% compared with alternatives), overall professional sentiment and financial characteristics for the stock Eli Lilly are above average. The 360° View is based on consolidating four consolidated indicators, with all four indicators above average for Eli Lilly. The consolidated Value Rank has an attractive rank of 57, which means that the share price of Eli Lilly is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 57% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 64, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The company is also safely financed with a Safety rank of 72. Finally, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 51. ...read more

more
Strongest Rank Price vs. Book (P/B)
Weakest Rank Profit Growth
Country USA
Industry Pharmaceuticals
Size XX-Large
Website lilly.com
Index
D.J. US Health Care
D.J. US Pharmaceutical
S&P 500
Eli Lilly stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 9-Apr-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
57 20 12 27
Growth
64 89 77 19
Safety
Safety
72 39 28 20
Sentiment
51 76 81 34
360° View
360° View
73 55 40 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
28 79 52 31
Opinions Change
49 62 52 48
Pro Holdings
n/a 48 91 45
Market Pulse
31 67 67 62
Sentiment
51 76 81 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
57 20 12 27
Growth
64 89 77 19
Safety Safety
72 39 28 20
Combined
83 43 22 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
46 5 3 16
Price vs. Earnings (P/E)
10 24 9 24
Price vs. Book (P/B)
7 1 1 4
Dividend Yield
99 84 85 86
Value
57 20 12 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
76 67 82 11
Profit Growth
100 90 29 36
Capital Growth
13 54 55 34
Stock Returns
32 69 87 87
Growth
64 89 77 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
14 18 19 13
Refinancing
88 14 17 7
Liquidity
72 61 89 93
Safety Safety
72 39 28 20

Similar Stocks

Discover high‑ranked alternatives to Eli Lilly and broaden your portfolio horizons.

Salesforce

NYQ:CRM
Country: USA
Industry: Application Software
Size: XX-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Microsoft

NSQ:MSFT
Country: USA
Industry: Systems Software
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

This is an all-around strong stock. It shows good value, high growth, safe financing, and positive professional sentiment. It is ideal for most buy-and-hold investors who value a good all-around stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews